诺诚健华(香港联交所代码:09969;上交所代码:688428)今日宣布,公司自主研发的新型TYK2抑制剂Soficitinib(ICP-332)治疗非节段型白癜风的II/III期临床试验在中国完成首例患者给药。ICP-332是诺诚健华具有全球自主知识产权的1类创新药,是高效、高选择性的新型口服TYK2抑制剂,开发用于治疗各种T细胞相关的自身免疫性疾病,包括白癜风、特应性皮炎、结节性痒疹等,...
Source Link诺诚健华(香港联交所代码:09969;上交所代码:688428)今日宣布,公司自主研发的新型TYK2抑制剂Soficitinib(ICP-332)治疗非节段型白癜风的II/III期临床试验在中国完成首例患者给药。ICP-332是诺诚健华具有全球自主知识产权的1类创新药,是高效、高选择性的新型口服TYK2抑制剂,开发用于治疗各种T细胞相关的自身免疫性疾病,包括白癜风、特应性皮炎、结节性痒疹等,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.